AstraZeneca's Lynparza meets main goal of late-stage cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for pancreatic cancer.

from Reuters: Health News https://ift.tt/2IQoCv1